Navigation Links
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
Date:5/17/2009

f Staphylococcus aureus in infected macrophages, (Poster P 1025). The final poster shows that NXL103 was active in vitro against both community-acquired and hospital-acquired strains of MRSA. The poster also showed that NXL103 was subject to a low spontaneous frequency of resistance (Poster P 1102).

It is Novexel's intention to seek partners for both the NXL104/ceftazidime combination and NXL103 in certain geographies.

All four posters will be available for download from Novexel's web site (http://www.novexel.com) shortly after the close of the ECCMID conference.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated US$17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by Novexel's partner, Forest Laboratories (NYSE: '/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
2. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
3. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
4. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
5. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
11. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. ... Phase 2 clinical program of NP001 for the treatment ... disease) are being highlighted today in an oral ... Research Group , being held in Bloomington, ... post hoc  analysis, administration of a high dose of ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. 17, 2014 ... a partnership in the fight against sarcoma. Under ... Alliance Suzanne Renee Leider Memorial Assistance Fund. ... to reimburse sarcoma patients for expenses directly related ... specialist. Scientific literature reinforces the importance of this ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
(Date:9/17/2014)... Historically, spaceflight has been reserved for the very ... meet the highest physical and psychological standards to ... the advent of commercial spaceflight, average people can ... has had very little information about what medical ... in the spaceflight environment, as most medical conditions ...
(Date:9/17/2014)... People who struggle to distinguish between a business strategy and ... get the answer by reading Per Wickstrom’s latest blog post. ... business plan and a business strategy are both strategic – ... way I view it is that a business plan is ... two.” , According to the blog post, a business ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
(Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Positive messages ... some people kick the habit, a new study suggests. ... responded better to "loss-framed" messages about the harmful effects ... quit whenever they want benefit more from "gain-framed," or ... The researchers concluded that using a mix of ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... University,s Physical Activity and Public Health Laboratory, active commuting ... can be an easy, effective and efficient way to ... Wittman, a K-State senior in kinesiology, Olathe, worked with ... of kinesiology, on the active commuting research. The project ...
... April 13 Mylan Inc. (Nasdaq: MYL ... banker,Andrew G. Cuneo as vice president of Global Business ... and strategic,efforts in close alignment with the company,s executive ... Chairman and CEO Robert J. Coury said: "Drew brings ...
... 13 Lionbridge,Technologies, Inc. (Nasdaq: ... testing,and development services today announced an alliance ... Enterprise Content Management (ECM) software,designed to ensure ... management solutions for pharmaceutical companies and other,organizations. ...
... could one day quickly detect if treatment is working, study ... technique that can detect subtle changes in cancer cells contained ... tissue may one day be used by doctors to better ... , "Currently, we don,t know what,s going on in a ...
... Though a high-fiber diet has long been considered good ... Medical College of Georgia researchers have discovered a reason ... Researchers report in the April issue of Cancer ... butyrate, a metabolite produced by fiber-eating bacteria in the ...
... 15th, there will be a,Capitol Hill briefing called ... and Mental Illness." Author and award winning ... HELP USA,Lamp Community, the National Alliance on Mental ... H.O.M.E. have join forces to host this,important briefing. ...
Cached Medicine News:Health News:Survey research looks at attitudes, obstacles to walking and biking to work 2Health News:Survey research looks at attitudes, obstacles to walking and biking to work 3Health News:Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development 2Health News:Lionbridge Announces Partnership with Open Text to Streamline Regulatory Compliance Solutions for Pharmaceutical Companies 2Health News:A Drop of Blood May Help Assess Cancer Therapy 2Health News:Colon cancer shuts down receptor that could shut it down 2Health News:Colon cancer shuts down receptor that could shut it down 3Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 2Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: